Jane Street
PRME icon

Jane Street’s Prime Medicine PRME Stock Holding History

Jane Street’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$523K Buy
150,200
+38,900
+35% +$148K ﹤0.01% 7951
2025
Q4 		$386K Sell
111,300
-9,800
-8% -$43.6K ﹤0.01% 8272
2025
Q3 		$671K Buy
+121,100
New +$492K ﹤0.01% 7200

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Jane Street's PRME Position: Q4 2025 in Review

Jane Street sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 85,892 shares — an estimated $382K sold.

Jane Street first reported a position in PRME in Q2 2023 and held it in 8 quarters. The position peaked at $5.82M in Q2 2023. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Jane Street reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 85,892 Prime Medicine shares in Q4 2025, an estimated $382K.
  • Jane Street first reported a position in Prime Medicine in Q2 2023 and held it in 8 quarters.
  • Jane Street's Prime Medicine position peaked at $5.82M in Q2 2023.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.